MR generic application [Regulatives / Guidelines]

posted by Mikkabel – Belgium, 2020-03-16 16:40 (397 d 19:26 ago) – Posting: # 21282
Views: 3,235

Dear everyone,

I have a question regarding the number of studies to be performed to get the MA for a MR formulation following a generic application.
Indeed, we are developing a generic formulation of a marketed modified release form. This MR forms is marketed with three dosages strengths X1, X2 and X3.

According to the section 6 of the Guideline on the pharmacokinetic and clinical evaluation
of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1), the following studies are required to demonstrate BE:
- a single-dose fasting study comparing test and reference drug product
- a single-dose fed study using a high-fat meal comparing test and reference drug product
- a multiple-dose study comparing test and reference drug product.

Furthermore, according to the section 6.1.2 "strength to be evaluated", the SD studies under fasting conditions should be performed for ALL strengths.

So, the question is, even if the product is eligible for the bracketing approach, is it necessary to perform the SD study with the lowest strength considering that the PK is linear for all the considered strengths?

Thanks in advance,
Best regards,

Complete thread:

Activity
 Admin contact
21,419 posts in 4,475 threads, 1,509 registered users;
online 11 (0 registered, 11 guests [including 3 identified bots]).
Forum time: Sunday 13:07 CEST (Europe/Vienna)

Nothing fails like success because you do not learn anything from it.
The only thing we ever learn from is failure.
Success only confirms our superstitions.    Kenneth E. Boulding

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5